MX2020008173A - Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos. - Google Patents

Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos.

Info

Publication number
MX2020008173A
MX2020008173A MX2020008173A MX2020008173A MX2020008173A MX 2020008173 A MX2020008173 A MX 2020008173A MX 2020008173 A MX2020008173 A MX 2020008173A MX 2020008173 A MX2020008173 A MX 2020008173A MX 2020008173 A MX2020008173 A MX 2020008173A
Authority
MX
Mexico
Prior art keywords
antimuscarinic
lipoic acid
anticholinergic agent
formula
combination
Prior art date
Application number
MX2020008173A
Other languages
English (en)
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2020008173A publication Critical patent/MX2020008173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente divulgación se refiere a composiciones farmacéuticas que comprende una cantidad terapéuticamente efectiva de un agente antimuscarínico o de uno anticolinérgico, o de una sal o de un estereoisómero farmacéuticamente aceptable de los mismos, en combinación con una cantidad terapéuticamente efectiva de ácido lipoico, o de una sal o de un estereoisómero farmacéuticamente aceptable del mismo. El agente antimuscarínico o anticolinérgico es un compuesto de la Fórmula I, Formula II, o Formula III, y el ácido lipoico es un compuesto de la Fórmula IV o Formula V. La composición farmacéutica es una mezcla física de un agente antimuscarínico o de uno anticolinérgico y ácido lipoico.
MX2020008173A 2018-02-05 2019-02-05 Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos. MX2020008173A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841004306 2018-02-05
IN201841008091 2018-03-05
PCT/IB2019/050901 WO2019150341A1 (en) 2018-02-05 2019-02-05 Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof

Publications (1)

Publication Number Publication Date
MX2020008173A true MX2020008173A (es) 2020-09-25

Family

ID=67480013

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008173A MX2020008173A (es) 2018-02-05 2019-02-05 Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos.

Country Status (13)

Country Link
US (2) US20200375961A1 (es)
EP (1) EP3749303A4 (es)
JP (1) JP2021512876A (es)
KR (1) KR20200118128A (es)
AU (1) AU2019214557A1 (es)
BR (1) BR112020015436A2 (es)
CA (1) CA3089894A1 (es)
IL (1) IL276350A (es)
MX (1) MX2020008173A (es)
RU (1) RU2020122659A (es)
SG (1) SG11202006492SA (es)
WO (1) WO2019150341A1 (es)
ZA (1) ZA202004058B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3522873T3 (da) * 2016-10-04 2022-06-20 Cellix Bio Private Ltd Sammensætninger og fremgangsmåder til behandlingen af xerostomi
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CA3178653A1 (en) * 2020-05-26 2021-12-02 Mahesh Kandula Pharmaceutical formulations of pilocarpine r-(+)-lipoate
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
WO2023052977A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Compositions, methods and uses thereof
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
CN116459251A (zh) * 2022-01-18 2023-07-21 苏州普乐康医药科技有限公司 一种含西维美林的眼用制剂及其制备方法和应用
TW202329958A (zh) * 2022-01-25 2023-08-01 張金明 西維美林水溶液組合物和使用方法
WO2023143575A1 (zh) * 2022-01-29 2023-08-03 南京济群医药科技股份有限公司 一种m-胆碱受体激动剂化合物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608073A (en) * 1968-07-16 1971-09-21 Barnes Hind Pharm Inc Emulsion of pilocarpine for ophthalmic use
CA2566873C (en) * 2004-05-20 2013-02-12 Diamedica Inc. Use of drug combinations for treating insulin resistance
JP2006070027A (ja) * 2004-08-06 2006-03-16 Dai Ichi Seiyaku Co Ltd 口腔粘膜投与剤
US20110150974A1 (en) * 2004-08-06 2011-06-23 Daiichi Pharmaceutical Co., Ltd. Agent For Oral Mucosal Administration
EP1965787B1 (en) * 2005-11-30 2013-04-10 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
UA86441C2 (ru) * 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
US20090263467A1 (en) * 2008-04-21 2009-10-22 Hemant Narahar Joshi Combination drug therapy using orally dissolving film or orally disintegrating tablet dosage forms to treat dry mouth ailments
PT2442645E (pt) * 2009-06-15 2014-11-05 Encore Health Llc Ésteres de colina
US9149454B2 (en) * 2009-11-12 2015-10-06 Acacia Pharma Limited Use of bethanechol for treatment of xerostomia
US10507245B2 (en) * 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
KR101586789B1 (ko) * 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9427144B2 (en) * 2014-01-03 2016-08-30 Ophthalmx Llc Methods and systems for detecting ophthalmic disease
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
DK3522873T3 (da) * 2016-10-04 2022-06-20 Cellix Bio Private Ltd Sammensætninger og fremgangsmåder til behandlingen af xerostomi
MX2020004666A (es) * 2017-11-17 2022-01-26 Cellix Bio Private Ltd Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
JP2022516796A (ja) * 2019-01-12 2022-03-02 セリックス バイオ プライヴェート リミテッド 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用

Also Published As

Publication number Publication date
RU2020122659A (ru) 2022-03-09
ZA202004058B (en) 2021-08-25
EP3749303A4 (en) 2022-01-26
JP2021512876A (ja) 2021-05-20
US20230310391A1 (en) 2023-10-05
AU2019214557A1 (en) 2020-08-20
IL276350A (en) 2020-09-30
US20200375961A1 (en) 2020-12-03
SG11202006492SA (en) 2020-08-28
EP3749303A1 (en) 2020-12-16
BR112020015436A2 (pt) 2020-12-22
CA3089894A1 (en) 2019-08-08
WO2019150341A1 (en) 2019-08-08
KR20200118128A (ko) 2020-10-14

Similar Documents

Publication Publication Date Title
MX2020008173A (es) Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos.
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
PH12018500377A1 (en) Novel annelated benzamides
WO2011008054A3 (ko) Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 부틸산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
IL276194B2 (en) Pharmaceutical compounds or preparations containing them for use in the treatment of pain
PH12020551342A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
PH12021550557A1 (en) Furo[3,4-b]pyrrole-containing btk inhibitor
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
WO2021044231A3 (es) Compuestos de curcumina y aminoácidos básicos